Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
NCT02593227
Completed
This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2021
Locations: University of Kansas Cancer Center, Westwood, Kansas
Conditions: Breast Cancer
Register for Updates
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
NCT04762511
Terminated
The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered intramuscularly (IM) on a 0, 2-month schedule to healthy participants aged 18-40 years.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
06/24/2021
Locations: GSK Investigational Site, Lenexa, Kansas
Conditions: Herpes Simplex
Register for Updates
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
NCT02045836
Completed
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Wichita, Kansas
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
NCT02075515
Completed
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Wichita, Kansas
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
NCT02184572
Completed
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/15/2020
Locations: GSK Investigational Site, Augusta, Kansas +2 locations
Conditions: Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Register for Updates
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
NCT01681992
Completed
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/15/2020
Locations: GSK Investigational Site, Wichita, Kansas
Conditions: Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Register for Updates
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
NCT02388165
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: University of Kansas Hospital, Kansas City, Kansas +1 locations
Conditions: Staphylococcal Vaccine
Register for Updates
Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults
NCT04227210
Completed
This study evaluates an investigational vaccine designed to protect humans against infection with respiratory syncytial virus (RSV). The investigational vaccine (MV-012-968) is administered as drops in the nose. This study specifically analyzes the safety of, and the immune response to, the vaccine when administered to healthy non-pregnant adults between the ages of 18 and 40 years.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
09/13/2020
Locations: Johnson County Clin-Trials, Lenexa, Kansas
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT01266460
Completed
This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/21/2020
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
Register for Updates
Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
NCT01122784
Completed
Multicenter, randomized, single-blinded comparison of two formulations of the rF1V vaccine at a single dosage of 80 µg and two 3-dose schedules in 400 healthy, adult volunteers in four parallel cohorts. Two rF1V vaccine cohorts (N=160 each) and two rF1V antigen-only cohorts (N=40 each) will be vaccinated at two different three-dose schedules (Days 0, 56 and 182 or Days 0, 56 and 121).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/28/2020
Locations: Johnson County Clinical Trials, Lenexa, Kansas +1 locations
Conditions: Plague Vaccine
Register for Updates
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
NCT03314662
Completed
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/20/2020
Locations: Johnson County Clin-Trials, Lenexa, Kansas +2 locations
Conditions: Influenza, Human
Register for Updates
BARDA Securing Anthrax Immunity For the Elderly
NCT03518125
Completed
This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax vaccines to generate an immune response in adults ≥ 66 years of age in stable health in comparison to adults 18-50 years of age in stable health.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/13/2020
Locations: Johnson County Clin-Trials, Lenexa, Kansas
Conditions: Anthrax
Register for Updates